Minerva Neurosciences Inc (NERV) had a good day on the market for Tuesday December 10 as shares jumped 9.01% to close at $7.38. About 606,031 shares traded hands on 5,837 trades for the day, compared with an average daily volume of n/a shares out of a total float of 39.03 million. After opening the trading day at $6.86, shares of Minerva Neurosciences Inc stayed within a range of $7.50 to $6.61.
With today’s gains, Minerva Neurosciences Inc now has a market cap of $288.01 million. Shares of Minerva Neurosciences Inc have been trading within a range of $8.83 and $4.02 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson’s disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson’s disease.
Minerva Neurosciences Inc is based out of Waltham, MA and has some 14 employees. Its CEO is Remy Luthringer.
Minerva Neurosciences Inc is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.